Zealand Pharma Ownership
ZLDPF Stock | USD 101.61 0.64 0.63% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Zealand |
Zealand Pink Sheet Ownership Analysis
About 56.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 3.26. Zealand Pharma AS had not issued any dividends in recent years. Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 237 people.The quote for Zealand Pharma AS is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call Adam MD at 45 88 77 36 00 or visit https://www.zealandpharma.com.Currently Active Assets on Macroaxis
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.